Discover the latest HBM4EU research update
Named 'Priority Substances and Cancer', our latest research brief provides an overview of HBM4EU priority substances and their carcinogenic properties.
Human biomonitoring (HBM) can play a key role in assessing the real-life exposure to carcinogenic chemicals and ultimately in the calculation of increased cancer risk. This application is at the heart of the HBM4EU prioritization strategy and supports EU policies aimed at cancer prevention, such as the Beating Cancer Plan.
“Cancer impacts the lives of millions of Europeans, with well over 3 million new patients diagnosed each year, almost 2 million deaths, and severe consequences for the economy and health systems of EU countries (3,4). About 23 % of cancer cases globally happen in Europe, although it is home to only 9 % of the world’s population (5). In Europe, cancer is the most frequent form of non-communicable disease and the second most common cause of death”
Download the full brief here.
Disclaimer
The HBM4EU project was launched in 2016 with the aim of improving the collective understanding of human exposure to hazardous chemicals and developing HBM as an exposure assessment method. The project had €74m in funding and jointly implemented by 120 partners from 28 participating countries – 24 EU member states plus Norway, Switzerland, Iceland and Israel and the European Environment Agency. One of its aims was to ensure the sustainability of HBM in the EU beyond 2021. The project ended in June 2022. The website will not be updated any longer, except the page on peer reviewed publications, but will be online until 2032.
